News

Zacks Investment Research on MSN1h
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, ...
GSK and Dalhousie University Collaborate to Address Health Equity Gaps through the GSK Vaccinology and Health Equity Fellowship Award
Dr. Stephana Julia Moss, an investigator at the Canadian Center for Vaccinology (CCfV), Dalhousie University, has been ...
AstraZeneca, GSK shares down after Trump threatens drug import tariffs
Investing.com -- Shares of AstraZeneca (ST: AZN) and GlaxoSmithKline (LON: GSK) fell Tuesday after former U.S. President ...
Severe Asthma Market Set for Robust Growth Through 2034, Driven by Breakthrough Biologics and Emerging Pipeline Therapies | DelveInsight
The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...
GSK Licenses Shigella Vaccine to Bharat Biotech
GSK plc (NYSE:GSK) is one of the 12 best healthcare stocks to buy now. On June 12, the company announced licensing its ...
GlaxoSmithKline Pharmaceuticals Shares Decline by 2.21% in Today's Trading
GlaxoSmithKline Pharmaceuticals, with its shares currently priced at Rs 3,292.30, remains a key stock to watch, particularly ...
Drug Target Review6d
A spatial approach to understanding drug dynamics using mass spectrometry imaging
What if you could actually see where a drug travels in the body down to the cellular level. Find out how mass spectrometry ...
Newseria BIZNES6d
IPV Vaccines Market Set to Expand at CAGR of 8.7% Through 2032 | Sanofi Pasteur, GlaxoSmithKline plc
The global IPV vaccines market is estimated to be valued at USD 199.9 Mn in 2025 and expected to reach at USD 358.5 Mn by 2032 With a CAGR of 8.7% during the forecast period (2025-2032). Coherent ...